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Defibrotide in preventing veno-occlusive disease  
after hematopoietic stem cell transplantation  
in children with osteopetrosis
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A 5-month-old girl diagnosed with osteopetrosis (OP) 
caused by homozygous mutation in the SNX10 gene was 
admitted to the Department of Pediatric Bone Marrow 
Transplantation, Oncology and Hematology in Wroclaw, 
Poland for high-dose chemotherapy with subsequent allo-
geneic hematopoietic stem cell transplantation (allo-HSCT).
The infant was born at gestational age 41 weeks with 
Apgar score 10. Antenatal period was uneventful. The new-
born’s hearing screening test revealed no abnormalities. 
The patient’s family history was notable for osteopetrosis 
confirmed in a brother who had died aged 4. An older sis-
ter was healthy. In the course of diagnostics, normocytic 
anemia with reticulocytosis, and elevated levels of ferritin, 
lactate dehydrogenase (LDH), creatine kinase-myocardi-
al bound (CK-MB) and vitamin A were found. Myelogram 
showed reduced cellularity of bone marrow in each lineage, 
with absence of megakaryocytes. Bone X-ray showed an 
increase in bone sclerosis with blurred trabeculae struc-
ture, but no pathologic fractures were detected. The con-
ditioning regimen consisted of busulfan intravenous (i.v.) 
(4 ×4 ×1 mg/kg), fludarabine (5 ×30 mg/m2) and thiote-
pa (2 ×5 mg/kg). Cyclosporin A was implemented for the 
prevention of graft rejection and graft versus host dis-
ease (GvHD) from day –1 before hematopoietic stem cell 
transplantation (HSCT). Ursodeoxycholic acid was admin-
istered from day –12 as the routine prevention of hepatic 
veno-occlusive disease (VOD). The patient received pro-
phylactic defibrotide (off-label) (25 mg/kg/day) from day 
+2 after HSCT onwards. Bone marrow transplantation from 
her 10/10 humen leukocyte antigen (HLA)-matched sister 
was performed. 6.81 ×106 CD34+ cells/kg were infused.
On day +20, hepatomegaly was diagnosed by palpation 
of the abdomen with the detection of the liver 3.5 cm below 
costal margin and then confirmed by abdominal ultrasound 
(enlarged liver size approximately 8.1 cm with increased 
echogenicity and features of steatosis without focal chan-
ges). Weight gain requiring implementation of furosemide, 
increased consumption of platelets with normalization after 
weight-adjusted platelet substitution, rising bilirubin from 
a baseline value up to 1.4 mg/dl with fast normalization, 
decreased antithrombin III activity, and enlarged abdomi-
nal circumference were observed.
The patient was diagnosed with mild VOD based on the 
European Society for Blood and Marrow Transplantation 
(EBMT) criteria (Table I) due to the presence of the following: 
weight gain >5% above baseline value; and hepatomegaly 
confirmed by ultrasound [1]. She was also treated with spi-
ronolactone from day +20 for two days with drug withdrawal 
due to hyperkaliemia and hyponatremia. Defibrotide was im-
plemented prophylactically on day +2, and was continued 
during the VOD course. No side effects of long-term therapy 
with defibrotide were observed during hospitalization. The 
patient’s condition began to improve with normalization of 
bilirubin level and weight, and hepatomegaly resolution. 
VOD symptoms resolved on day +27, and defibrotide was 
stopped on day +30 thereafter. The child was discharged 
on day +41 without significant adverse events.
A 2-year follow-up revealed no neurological symptoms, 
and the psychomotor development of the girl was satisfac-
tory. No late hepatic VOD was observed.
Osteopetrosis is a genetic disorder with heterogeneo-
us clinical phenotypes, characterized by excessively high 
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bone density caused by defects in the formation or fun-
ction of osteoclasts [2]. Three forms of osteopetrosis have 
been described: autosomal recessive osteopetrosis (ARO), 
autosomal dominant osteopetrosis, and X-linked osteope-
trosis [3]. The diagnosis of ARO, the most severe of the 
three forms, is made soon after birth. Left untreated it is 
lethal, with a mortality rate of 70% by age 6 [4]. OP requi-
res a distinct strategy and personalized management. The-
rapeutic options are limited, and HSCT remains the only 
life-saving method. HSCT should be performed as soon as 
possible in children with OP, preferably before the age of 
10 months [2], thereby preventing irreversible complica-
tions regarding vision, hearing and/or hematopoiesis dys-
function [5]. Recipients of HLA-identical HSCT appear to 
have a 5-year disease-free survival of approximately 73% 
[6]. Patients with ARO have a higher incidence of VOD af-
ter HSCT than do children with other underlying diseases 
(63.6% vs. 10–30%) [7]. Prophylaxis of VOD includes im-
plementation of ursodeoxycholic acid and defibrotide (off-
-label) [8]. Defibrotide adverse effects include diarrhea, 
nausea, vomiting, epistaxis, hypotension, pulmonary al-
veolar hemorrhage, cerebral hemorrhage and sepsis [9]. 
Deciding which patients should receive defibrotide as VOD 
prophylaxis remains the subject of debate.
In describing this case, we intended to emphasize the 
importance of this off-label prophylactic method in this spe-
cific cohort of patients. In our Department, we adapted the 
expert recommendations of Corbacioglu et al. [7] and gave 
off-label defibrotide at 25 mg/kg/day as a prophylaxis of 
VOD after HSCT. In the described patient, only a mild form 
of VOD developed and the child did not require treatment 
in a pediatric intensive care unit.
The outcome of our patient confirms the conclusion 
of Corbacioglu et al. [10] controlled trial in which the rate 
of VOD was lower in patients with OP receiving defibrotide 
prophylaxis compared to controls.
In conclusion, off-label VOD prophylaxis with defibroti-
de significantly reduced the severity of VOD in our patient, 
and ensured a mild post-transplant course and swift dis-
charge home. The benefits clearly outweighed the possible 
complications of using prophylactic defibrotide.
VOD is a complication which increases the risk of trans-
plant-related mortality, as well as affecting the quality of 
life of a child. Therefore, the implementation of prophyla-
ctic defibrotide before HSCT seems reasonable and fully 
justified in this high-risk group of patients.
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Table I. European Society for Blood and Marrow Transplantation 
(EBMT) diagnostic criteria for hepatic sinusoidal obstruction syn-
drome/veno-occlusive disease (SOS/VOD) in children [1]
No limitation for time of onset of SOS/VOD
The presence of two or more of the following*:
• unexplained consumptive and transfusion-refractory 
thrombocytopenia**
• otherwise unexplained weight gain on three consecutive 
days despite use of diuretics or weight gain >5% above 
baseline value
• hepatomegaly*** (best if confirmed by imaging) above 
baseline value
• ascites*** (best if confirmed by imaging) above baseline 
value
• bilirubin rising from baseline value or bilirubin ≥2 mg/dL 
within 72 h
*With the exclusion of other potential differential diagnoses; **≥1 weight-adjusted platelet sub-
stitution/day to maintain institutional transfusion guidelines; ***suggested: imaging [ultrasound 
(US), computed tomography (CT) or magnetic resonance imaging (MRI)] immediately before 
hematopoietic cell transplantation (HCT) to determine baseline value for both hepatomegaly and 
ascites
